

(C) WPI/Derwent

AN - 1983-49916K [21]
 AP - JP19810159869 19811007
 CPY - YOSH-I
 DC - B04
 DR - 0035-U
 FS - CPI
 IC - A61K31/37 ; A61K35/54
 MC - B03-F B04-B04M B12-C10 B12-E01 B12-H01 B12-H03
 M1 - [01] M423 M431 M782 M903 P520 P522 P814 V600 V645
 M2 - [02] F012 F013 F014 F015 F113 H4 H403 H421 H482 H8 J5 J522 K0 L8 L818
 L821 L832 L9 L942 L960 M280 M312 M321 M332 M343 M373 M391 M413 M431
 M510 M521 M530 M540 M782 M903 M910 P520 P522 P814 V0 V330
 PA - (YOSH-I) YOSHIHIRO F
 PN - JP58062117 A 19830413 DW198321 004pp
 - JP63013405B B 19880325 DW198816 000pp
 PR - JP19810159869 19811007
 XA - C1983-048512
 XIC - A61K-031/37 ; A61K-035/54
 AB - J58062117 The agent contains freeze-dried yolk, (2200 dry pts. wt.)
 and vitamin C, 1-70 dry pts. wt. (pref. 10-40 pts. wt)
 - The freeze-drying gives powder or granular mixture without
 denaturation of components of the yolk, such as protein, enzyme and
 cholesterol, and vitamin C. The freeze-drying is pref. effected at
 below -70 deg.C. (0.01-0.001 mmHg).
 - The agent is useful for vascular diseases such as cerebral apoplexy or
 myocardial infarction. The agent increases 12 mg/ dl of HDL
 cholesterol in blood after 2 months continuous administration, and
 reduces index of arteriosclerosis greatly though the prior agents
 increase about 10 mg/dl after 3 months admin. and reduce the index
 slightly.
 IW - ANTI ARTERIOSCLEROSIS AGENT DERIVATIVE YOLK VITAMIN-C
 IKW - ANTI ARTERIOSCLEROSIS AGENT DERIVATIVE YOLK VITAMIN-C
 NC - 001
 OPD - 1981-10-07
 ORD - 1983-04-13
 PAW - (YOSH-I) YOSHIHIRO F
 TI - Anti:arteriosclerotic agent - derived from yolk and vitamin=C